Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Mycosis Fungoides

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Mycosis Fungoides

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Derived from NCI topic(s): Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
      source wording
      Source null
      4 more-specific settings
      ADCETRIS: recurrent Mycosis Fungoides after prior therapy →Stage I Mycosis Fungoides →Stage III Mycosis Fungoides →recurrent Mycosis Fungoides →

      Study evidence for this setting

      7 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00047060 · Registry condition search · Scope: narrower

      Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00985140 · Registry condition search · Scope: narrower

      Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01578499 · Source cited / selected · Scope: narrower

      A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

      6 outcome links · 2 safety-group records · 8 quality-of-life measures

      →

      NCT03075553 · Registry condition search · Scope: narrower

      Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03598998 · Registry condition search · Scope: narrower

      Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

      4 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT03905135 · Registry condition search · Scope: narrower

      Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT04101331 · Registry condition search · Scope: narrower

      Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

      6 outcome links · 1 safety-group records · 2 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-mycosis-fungoides
        binding id
        ncit-C3246
        source collection
        ncit-concept
        source key
        C3246
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice